[CDSCO insights](https://indusdesk.com/cdsco/insights/)

# PSUR timelines for new drugs start from the date of marketing

https://indusdesk.com/cdsco/insights/psur-timelines-for-new-drugs-start-from-the-date-of-marketing/

The Central Drugs Standard Control Organization issued File No. PSUR/4/2026-eoffice on April 21, 2026. CDSCO's advisory of April 21, 2026 says PSUR timelines for new drugs start from the date of actual marketing, even if approval was granted earlier. It applies to manufacturers and importers of new drugs.

CDSCO · April 21, 2026

Vishnu Gupta

The Central Drugs Standard Control Organization (CDSCO), through the Post Marketing Drugs Safety Monitoring Division of the Office of the Drugs Controller General (India), Directorate General of Health Services, issued an advisory under File No. PSUR/4/2026-eoffice, dated April 21, 2026. Its subject is the submission of Periodic Safety Update Reports (PSURs) for new drugs via the SUGAM portal on a deferred basis where marketing is delayed after approval. It is signed by Dr. R Chandrashekar, Joint Drugs Controller (India), with copies to all stakeholders through the CDSCO website and to all CDSCO zonal and sub-zonal offices.

The advisory recalls that, under the Fifth Schedule of the New Drugs and Clinical Trials Rules, 2019 and relevant CDSCO guidelines, manufacturers and importers of new drugs must submit PSURs as part of post marketing surveillance. CDSCO says it has observed that some applicants obtain approval to market a new drug but launch it later, and then submit PSUR data from the date of approval instead of the date of launch, losing valuable safety insights.

CDSCO directs all manufacturers and importers to ensure strict compliance with two points. First, PSUR submission timelines shall commence from the date of actual marketing of the new drug, even if approval was granted earlier. Second, all dosage forms, formulations and indications of a new drug should ordinarily be covered in one PSUR, with separate presentations of data within it for different dosage forms, indications or separate populations, so as to avoid duplicate submission of PSUR applications.

The advisory sets no new PSUR frequency. Its body does not mention the SUGAM portal or explain the "deferred basis" in its subject. It does not say how the date of actual marketing is to be shown to CDSCO, gives no start date, and does not say what applies to PSURs already submitted from the date of approval.

**Issued by**: Central Drugs Standard Control Organization, Post Marketing Drugs Safety Monitoring Division, Office of the Drugs Controller General (India), Directorate General of Health Services

**Document**: Advisory, File No. PSUR/4/2026-eoffice

**Dated**: April 21, 2026

**Applies to**: Manufacturers and importers of new drugs

**Basis cited**: Fifth Schedule, New Drugs and Clinical Trials Rules, 2019, and relevant CDSCO guidelines

**PSUR timelines start**: From the date of actual marketing of the new drug, even if approval was granted earlier

**One PSUR covers**: Ordinarily all dosage forms, formulations and indications, with separate presentations of data for different dosage forms, indications or separate populations

**PSUR frequency**: No new frequency set

**Takes effect**: No date stated

**Listed**: CDSCO Public Notices and Circulars, April 21, 2026

**Related**: Draft G.S.R. 504(E), June 22, 2026 (CG-DL-E-25062026-273835): would insert a proviso in the Fifth Schedule after para 1(5)(C)(iii) on how often PSURs are submitted, from approval until the drug product is marketed, for new drugs under clauses (iv) and (v) of rule 2(1)(w); no final rule on CDSCO's list of Gazette notifications, read October 28, 2026

**Signed by**: Dr. R Chandrashekar, Joint Drugs Controller (India)

[The advisory](https://files.indusdesk.com/cdsco/advisories/2026/psurs-for-new-drugs-on-deferred-basis-in-case-of-delayed-marketing.pdf) (PDF, 341 KB)

Source: [CDSCO's own copy](https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/Advisory.pdf).

Checked against the official copy on October 28, 2026.

- [CDSCO guide](https://indusdesk.com/cdsco/)

- [All CDSCO insights](https://indusdesk.com/cdsco/insights/)
